Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akrimax Pharmaceuticals, a specialty pharmaceutical company that acquires, markets, and develops products to address disease states related to cardiovascular, metabolic and endocrine diseases, has introduced NitroMist (Nitroglycerin Lingual Aerosol) 400mcg/Spray for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.
Subscribe to our email newsletter
Akrimax Pharma claims that NitroMist belongs to a group of drugs called nitrates. Nitroglycerin dilates (widens) blood vessels, making it easier for blood to flow through them and easier for the heart to pump.
NitroMist is available in a fully sealed aerosol delivery system, providing a shelf life of 36 months. NitroMist contains no ethyl alcohol.
Akrimax president and CEO Wayne Anderson said NitroMist is the second new product that Akrimax has brought to market in the past year.
"Akrimax also has expanded its sales force by a third in order to educate health care providers about NitroMist and its other promoted brands, Tirosint and Inderal LA," Anderson said.